Acusphere, Inc. is a pharmaceutical company, which engages in the development of drugs and formulations of existing drugs using proprietary micro particle technology. The company is headquartered in Lexington, Massachusetts. The company went IPO on 2003-10-08. The firm is focused on the development of Imagify, which contains Perflubutane Polymer Microspheres for injectable suspension. The firm's product Imagify is a cardiovascular drug for the detection of coronary artery disease (CAD). Imagify injectable suspension consists of porous, synthetic polymer microspheres containing gas that are administered intravenously and act as tracers of blood flow or perfusion. The firm has submitted the Marketing Authorization Application (MAA) for its lead product candidate, Imagify lyophilisate for dispersion for injection with the European Medicines Agency (EMA) to support the regulatory review of Imagify in the European Union (EU).
Follow-Up Questions
Acusphere Inc (ACUS)의 PER은 얼마입니까?
Acusphere Inc의 PER은 0입니다
Acusphere Inc의 CEO는 누구입니까?
Mr. Mark Leuchtenberger은 2013부터 회사에 합류한 Acusphere Inc의 President입니다.
ACUS 주식의 가격 성능은 어떻습니까?
ACUS의 현재 가격은 $0이며, 전 거래일에 decreased 0% 하였습니다.
Acusphere Inc의 주요 사업 주제나 업종은 무엇입니까?
Acusphere Inc은 Pharmaceuticals 업종에 속하며, 해당 부문은 Health Care입니다
